Syngene CEO On Sub-Dynamics As US Biotech Funding Finds New Normal, ADC Capabilities
Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and partnerships with big pharma are some of the other topics the former AstraZeneca executive discussed.
You may also be interested in...
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.
Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.